ESMO Clinical Practice Guidelines: Breast Cancer [Apri]
ClinicalTrial.gov. A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Rugo HS, et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). ESMO 2022. Abstract LBA76. [Apri]